RxDoctor Payments Data

William Whitten, MD

Family Medicine · Columbus, GANPI 1548261480

Payments from drug & device makers

$8,928in general payments, 2019–2025

Across 573 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$1K
  • Boehringer Ingelheim$649
  • AstraZeneca$571
  • GSK$458
  • Astellas Pharma US Inc$446
  • plus $4K from 42 others

What the payments were for

  • Food & beverage$8,928100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,928 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$145,747
Medicare patients
261
Services billed
40,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide83$120,658
MounjaroTirzepatide68$76,688
JardianceEmpagliflozin99$75,053
EliquisApixaban56$57,724
XareltoRivaroxaban24$22,836
JanumetSitagliptin Phos/Metformin Hcl20$20,587
Repatha SyringeEvolocumab27$20,440
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$20,230
FarxigaDapagliflozin Propanediol20$19,485
MyrbetriqMirabegron31$16,746
JanuviaSitagliptin Phosphate17$16,452
BreynaBudesonide/Formoterol Fumarate17$4,235
Atorvastatin Calcium341$3,812
Aspirin-Dipyridamole ErAspirin/Dipyridamole11$3,311
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,280$120,65883 claims
Lilly USA, LLCMounjaro$337$76,68868 claims
Boehringer IngelheimJardiance$649$75,05399 claims
PfizerEliquis$239$57,72456 claims
MerckJanumet, Januvia$70$37,03937 claims
Johnson & JohnsonXarelto$381$22,83624 claims
GSKTrelegy Ellipta$458$20,23015 claims
AstraZenecaFarxiga$571$19,48520 claims
Astellas Pharma US IncMyrbetriq$446$16,74631 claims
AbbVieSynthroid$1,045$1,39426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →